Sartorius Stedim Biotech SA
PAR:DIM

Watchlist Manager
Sartorius Stedim Biotech SA Logo
Sartorius Stedim Biotech SA
PAR:DIM
Watchlist
Price: 175 EUR 3.8% Market Closed
Market Cap: 17B EUR
Have any thoughts about
Sartorius Stedim Biotech SA?
Write Note

Gross Margin
Sartorius Stedim Biotech SA

41.8%
Current
50%
Average
43.8%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
41.8%
=
Gross Profit
1.1B
/
Revenue
2.7B

Gross Margin Across Competitors

Country FR
Market Cap 17B EUR
Gross Margin
42%
Country US
Market Cap 1.3T USD
Gross Margin
55%
Country US
Market Cap 196.3B USD
Gross Margin
41%
Country US
Market Cap 170.3B USD
Gross Margin
60%
Country KR
Market Cap 66.5T KRW
Gross Margin
50%
Country CH
Market Cap 37.6B CHF
Gross Margin
29%
Country US
Market Cap 38.5B USD
Gross Margin
55%
Country US
Market Cap 36.7B USD
Gross Margin
35%
Country US
Market Cap 26.4B USD
Gross Margin
59%
Country US
Market Cap 23B USD
Gross Margin
35%
Country US
Market Cap 22.3B USD
Gross Margin
64%
No Stocks Found

Sartorius Stedim Biotech SA
Glance View

Market Cap
17B EUR
Industry
Life Sciences Tools & Services

Sartorius Stedim Biotech SA, a key player in the biopharmaceutical industry, has positioned itself at the forefront of innovation in bioprocessing and laboratory solutions. Established in the early 2000s through the merger of Sartorius AG's biotech division and Stedim S.A., the company’s mission centers on enabling the development and production of life-saving biologics. With a comprehensive portfolio that includes bioprocessing equipment, research services, and laboratory instruments, Sartorius caters to a vast array of customers, from small biotech firms to large pharmaceuticals, ensuring seamless workflows in drug development and manufacturing. By leveraging cutting-edge technologies and maintaining a commitment to sustainability, Sartorius has built a reputation as a trusted partner in the industry, addressing the growing demand for effective therapies amidst an ever-evolving healthcare landscape. As the global biopharmaceutical market expands, driven by advancements in personalized medicine and precision therapies, Sartorius is well-positioned to capitalize on these trends. The company’s recent strategic acquisitions and investments in digitalization and automation enhance its product offerings, allowing clients to improve efficiencies and reduce time-to-market for essential therapeutics. Boasting a strong financial track record and a commitment to research and development, Sartorius Stedim Biotech SA not only ensures consistent growth but also aligns with long-term health sector trends. For investors, this combination of strategic vision, robust market position, and innovative capabilities makes Sartorius an attractive investment opportunity in the booming biotechnology sector.

DIM Intrinsic Value
159.09 EUR
Overvaluation 9%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
41.8%
=
Gross Profit
1.1B
/
Revenue
2.7B
What is the Gross Margin of Sartorius Stedim Biotech SA?

Based on Sartorius Stedim Biotech SA's most recent financial statements, the company has Gross Margin of 41.8%.